Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 8:02 PM
Ignite Modification Date:
2025-12-25 @ 5:35 PM
NCT ID:
NCT02282904
Group ID:
EG000
Title:
CGD Recipient
Description:
CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
Sirolimus: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Donor peripheral blood stem cells.: Infuse donor graft.
Cyclophosphamide post transplant: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Total body 200cGy: Day -1
Cyclophosphamide: 14.5 mg/kg IV over one hour Day -6 and -5
Fludarabine: 30 mg/m2 over 30 minutes Day -6 through Day -2
Busulfan: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
3
Serious Number At Risk:
7
Other Number Affected:
7
Other Number At Risk:
7
Study:
NCT02282904
Results Section:
NCT02282904
Adverse Events Module:
NCT02282904